WallStreetZenWallStreetZen

NYSEMKT: LCTX
Lineage Cell Therapeutics Inc Earnings & Revenue

LCTX past revenue growth

How has LCTX's revenue growth performed historically?
Company
-39.16%
Industry
169.3%
Market
17.86%
LCTX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
LCTX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
LCTX's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

LCTX earnings and revenue history

Current Revenue
$8.9M
Current Earnings
-$21.5M
Current Profit Margin
-240.2%

LCTX Return on Equity

Current Company
-31.3%
Current Industry
-63.4%
Current Market
188%
LCTX's Return on Equity (-31.3%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when LCTX announces earnings.

LCTX Return on Assets

Current Company
-19.9%
Current Industry
3.2%
LCTX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

LCTX Return on Capital Employed

Current Company
-28.04%
Current Industry
19.9%
LCTX's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

LCTX vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
LCTX$8.95M-$22.60M-$21.49M+12.39%N/A
GOSS$0.00-$161.92M-$179.82MN/AN/A
PRLD$0.00-$118.73M-$121.83MN/AN/A
RIGL$116.88M-$16.98M-$25.09M+21.30%N/A
FHTX$34.16M-$85.54M-$98.43M+428.05%N/A

LCTX earnings dates

Next earnings date
May 9, 2024

Lineage Cell Therapeutics Earnings & Revenue FAQ

What were LCTX's earnings last quarter?

On Invalid Date, Lineage Cell Therapeutics (NYSEMKT: LCTX) reported Q4 2023 earnings per share (EPS) of -$0.02, up 33.33% year over year. Total Lineage Cell Therapeutics earnings for the quarter were -$4.78 million. In the same quarter last year, Lineage Cell Therapeutics's earnings per share (EPS) was -$0.03.

If you're new to stock investing, here's how to buy Lineage Cell Therapeutics stock.

What was LCTX's earnings growth in the past year?

As of Q1 2024, Lineage Cell Therapeutics's earnings has grown year over year. Lineage Cell Therapeutics's earnings in the past year totalled -$21.49 million.

What is LCTX's earnings date?

Lineage Cell Therapeutics's earnings date is Invalid Date. Add LCTX to your watchlist to be reminded of LCTX's next earnings announcement.

What was LCTX's revenue last quarter?

On Invalid Date, Lineage Cell Therapeutics (NYSEMKT: LCTX) reported Q4 2023 revenue of $2.09 million up 9.03% year over year. In the same quarter last year, Lineage Cell Therapeutics's revenue was $1.92 million.

What was LCTX's revenue growth in the past year?

As of Q1 2024, Lineage Cell Therapeutics's revenue has grown -39.16% year over year. This is 208.46 percentage points lower than the US Biotechnology industry revenue growth rate of 169.3%. Lineage Cell Therapeutics's revenue in the past year totalled $8.95 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.